(MOPETT) Trial

More documents

Recommendations

Info

• Thrombolysis has been used for massive PE • Hemodynamic instability and shock • 5% of PEs qualify for standard dose • Concern about major bleeding and ICH • ICH 2-6% • Major bleeding 6-20%
• Standard dose t-PA 100mg in 2 hrs • Hesitancy of practitioners to use t-PA when patient is hemodynamically stable • Unresolved issue of concomitant parenteral anticoagulation with t-PA
Page 1 and 2: Moderate Pulmonary Embolism Treated
Page 3: Pulmonary Embolism • >100,000 ann
Page 7 and 8: “ SAFER DOSE t-PA”
Page 17 and 18: MOPETT Trial 121 Patients TT= 61 CG
Page 19 and 20: Secondary Endpoints • In-Hospital
Page 21 and 22: Evaluation of Troponin I and BNP Ec
Page 23 and 24: “Safe Dose” t-PA • For ≥ 50
Page 25: Concomitant Anticoagulation TG •
Page 29 and 30: Anticoagulation CG • Enoxaparin (
Page 31 and 32: TG CG p Value Initial PASPmm Hg 50
Page 33 and 34: Secondary Endpoints TG N= 61 CG N=6
Page 35: Changes in PASP ( mmHg )
Page 38: HAPPY NOWRUZ

(MOPETT) Trial

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?